Article
Vigil Neuroscience launches with a $50M Series A and two former Amgen neuroscience candidates
Rating:
0.0
Views:
82
Likes:
1
Library:
1
After more than 20 years in the industry, Ivana Magovčević-Liebisch had done it all — except build a company from scratch. Then Bruce Booth at Atlas Venture mentioned a couple of TREM2 assets he was trying to snag from Amgen's old neuroscience pipeline. “I came in to help them bring
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value